EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment

Scott Custo iD, Emma Tabone iD, Alexia Aquilina iD, Alex Gatt iD, Nicoletta Riva iD

Hämostaseologie · 01.08.2024 · 44 (04) · 242-254

DOI: 10.1055/a-2232-5480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hämostaseologie, erschienen am 01.08.2024. Verfasst von Scott Custo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Faculty of Medicine and Surgery, University of Malta, Msida, Malta. Hauptthemen laut MEDLINE: Anticoagulants, Venous Thrombosis, Splanchnic Circulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism occurring within the splanchnic venous system. Portal vein thrombosis is the most common presentation, while Budd–Chiari syndrome is the least common. Liver cirrhosis and abdominal solid cancer are the main local risk factors for SVT, whereas myeloproliferative neoplasms are the predominant systemic risk factors. Signs and symptoms of SVT are nonspecific and include abdominal pain, gastrointestinal bleeding, and ascites. Asymptomatic SVT is not uncommon, and the majority would be detected incidentally on routine abdominal imaging performed for the follow-up of liver diseases and tumors. The management of SVT aims to prevent thrombus progression, promote vessel recanalization, and prevent recurrent venous thromboembolism. Anticoagulation should be started early in order to increase the chances of vessel recanalization and reduce the risk of portal hypertension-related complications. Direct oral anticoagulants have been included in recent guidelines, as alternatives to vitamin K antagonists, after clinical stability has been reached; however, caution is required in patients with liver or kidney dysfunction. Treatment duration is based on the presence (or absence) and type (transient vs. permanent) of risk factors. This narrative review aims to summarize the latest evidence on SVT, with a particular focus on the anticoagulant treatment in special categories of patients (e.g., liver cirrhosis, solid cancer, myeloproliferative neoplasms, pancreatitis, incidentally detected SVT, Budd–Chiari syndrome, and chronic SVT).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsVenous ThrombosisSplanchnic CirculationHumansRisk FactorsPortal VeinBudd-Chiari SyndromeTreatment Outcome

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Medical School, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
  • Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.

ORCID-Profile: Scott Custo, Emma Tabone, Alexia Aquilina, Alex Gatt, Nicoletta Riva

Zitieren

APA

Custo, S., Tabone, E., Aquilina, A., Gatt, A., & Riva, N. (2024). Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment. Hämostaseologie, 44(04), 242-254. https://doi.org/10.1055/a-2232-5480

Vancouver

Custo S, Tabone E, Aquilina A, Gatt A, Riva N. Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment. Hämostaseologie. 2024;44(04):242-254. doi:10.1055/a-2232-5480

BibTeX
@article{Custo2024,
  author = {Custo, Scott and Tabone, Emma and Aquilina, Alexia and Gatt, Alex and Riva, Nicoletta},
  title = {Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment},
  journal = {Hämostaseologie},
  year = {2024},
  volume = {44},
  number = {04},
  pages = {242--254},
  doi = {10.1055/a-2232-5480}
}
Kostenlos starten →